CytoDyn ROE 2012-2025 | CYDY

Current and historical return on equity (ROE) values for CytoDyn (CYDY) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
CytoDyn ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2025-11-30 $-0.04B $-0.12B 38.14%
2025-08-31 $-0.02B $-0.10B 22.22%
2025-05-31 $0.00B $-0.10B -4.41%
2025-02-28 $-0.01B $-0.09B 7.29%
2024-11-30 $-0.01B $-0.09B 13.66%
2024-08-31 $-0.02B $-0.09B 17.47%
2024-05-31 $-0.05B $-0.12B 42.83%
2024-02-29 $-0.05B $-0.12B 46.09%
2023-11-30 $-0.06B $-0.11B 49.11%
2023-08-31 $-0.07B $-0.12B 64.89%
2023-05-31 $-0.09B $-0.11B 81.50%
2023-02-28 $-0.15B $-0.11B 148.91%
2022-11-30 $-0.18B $-0.12B 222.09%
2022-08-31 $-0.19B $-0.09B 346.19%
2022-05-31 $-0.21B $-0.09B 553.25%
2022-02-28 $-0.19B $-0.02B 953.09%
2021-11-30 $-0.20B $-0.01B 1045.33%
2021-08-31 $-0.19B $-0.03B 1107.25%
2021-05-31 $-0.18B $-0.02B 1717.07%
2021-02-28 $-0.18B $-0.02B 3345.45%
2020-11-30 $-0.18B $-0.01B 7000.00%
2020-08-31 $-0.16B $0.00B 3647.06%
2020-05-31 $-0.14B $0.00B 2074.07%
2020-02-29 $-0.08B $0.00B 964.71%
2019-11-30 $-0.06B $-0.01B 655.56%
2019-08-31 $-0.06B $-0.01B 773.33%
2019-05-31 $-0.06B $-0.01B 520.93%
2019-02-28 $-0.05B $-0.01B 434.04%
2018-11-30 $-0.06B $-0.01B 457.14%
2018-08-31 $-0.05B $-0.02B 392.59%
2018-05-31 $-0.05B $-0.01B 485.71%
2018-02-28 $-0.05B $-0.01B 640.00%
2017-11-30 $-0.04B $-0.01B 894.12%
2017-08-31 $-0.03B $-0.01B -12800.00%
2017-05-31 $-0.03B $0.00B -666.67%
2017-02-28 $-0.02B $0.01B -369.23%
2016-11-30 $-0.02B $0.01B -262.50%
2016-08-31 $-0.02B $0.01B -350.00%
2016-05-31 $-0.03B $0.01B -909.09%
2016-02-29 $-0.03B $0.01B 1320.00%
2015-11-30 $-0.03B $0.00B 496.00%
2015-08-31 $-0.03B $-0.01B 516.67%
2015-05-31 $-0.03B $-0.01B 625.00%
2015-02-28 $-0.01B $0.00B 5600.00%
2014-11-30 $-0.01B $0.00B -560.00%
2014-08-31 $-0.01B $0.00B -247.62%
2014-05-31 $-0.01B $0.00B -260.00%
2014-02-28 $-0.01B $0.01B -300.00%
2013-11-30 $-0.01B $0.01B -488.89%
2013-08-31 $-0.01B $0.00B 0.00%
2013-05-31 $-0.01B $0.00B 720.00%
2013-02-28 $-0.01B $0.00B 444.44%
2012-11-30 $-0.01B $0.00B 327.27%
2012-08-31 $-0.01B $-0.01B 188.24%
2012-05-31 $-0.01B $0.00B 133.33%
2012-02-29 $0.00B $0.00B 84.21%
2011-11-30 $0.00B $-0.01B 76.19%
2011-08-31 $0.00B $-0.01B 106.67%
2011-05-31 $0.00B $-0.01B 177.78%
2011-02-28 $-0.01B $0.00B 628.57%
2010-11-30 $-0.01B $0.00B 1466.67%
2010-08-31 $-0.01B $0.00B 1100.00%
2010-05-31 $-0.01B $0.00B 800.00%
2010-02-28 $0.00B $0.00B 266.67%
2009-11-30 $0.00B $0.00B 100.00%
2009-08-31 $0.00B $0.00B 100.00%
2009-05-31 $0.00B $0.00B 200.00%
2009-02-28 $0.00B $0.00B 200.00%
2008-11-30 $0.00B $0.00B 200.00%
2008-08-31 $0.00B $0.00B 100.00%
2008-05-31 $0.00B $0.00B 0.00%
2008-02-29 $0.00B $0.00B 100.00%
2007-11-30 $0.00B $0.00B 200.00%
2007-08-31 $0.00B $0.00B 300.00%
2007-05-31 $0.00B $0.00B 533.33%
2007-02-28 $-0.01B $0.00B 666.67%
2006-11-30 $0.00B $0.00B 800.00%
2006-08-31 $0.00B $0.00B 600.00%
2006-05-31 $0.00B $0.00B 266.67%
2006-02-28 $0.00B $0.00B 0.00%
2005-11-30 $0.00B $0.00B 0.00%
2005-08-31 $0.00B $0.00B 0.00%
2005-05-31 $0.00B $0.00B 0.00%
2005-02-28 $0.00B $0.00B 0.00%
2004-11-30 $0.00B $0.00B 0.00%
2004-08-31 $0.00B $0.00B 0.00%
2004-05-31 $0.00B $0.00B 0.00%
2004-02-29 $0.00B $0.00B 0.00%
2003-11-30 $0.00B $0.00B 0.00%
2003-08-31 $0.00B $0.00B 0.00%
2003-05-31 $0.00B $0.00B 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.317B $0.000B
CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed Phase 2 clinical trials with demonstrated antiviral activity in humans and is currently in Phase 3 development. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $92.346B 32.25
Takeda Pharmaceutical (TAK) Japan $56.926B 11.18
Zoetis (ZTS) United States $56.153B 20.10
BeOne Medicines - (ONC) Switzerland $38.812B 205.77
Sandoz Group AG (SDZNY) Switzerland $35.065B 0.00
Daiichi Sankyo, - (DSNKY) Japan $34.401B 17.13
United Therapeutics (UTHR) United States $20.898B 18.39
Merck (MKKGY) Germany $18.714B 11.54
Shionogi (SGIOY) Japan $18.571B 14.36
Neurocrine Biosciences (NBIX) United States $14.078B 33.78
Ionis Pharmaceuticals (IONS) United States $14.011B 0.00
IPSEN (IPSEY) France $13.491B 0.00
Summit Therapeutics (SMMT) United States $11.560B 0.00
Orion OYJ (ORINY) Finland $11.502B 32.86
Madrigal Pharmaceuticals (MDGL) United States $10.847B 0.00
Eisai (ESAIY) $8.574B 0.00
Ono Pharmaceutical (OPHLF) Japan $7.149B 17.10
Stevanato Group S.p.A (STVN) Italy $4.694B 26.27
Crinetics Pharmaceuticals (CRNX) United States $4.626B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $4.591B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $4.565B 21.67
Indivior Pharmaceuticals (INDV) United States $4.296B 17.53
Corcept Therapeutics (CORT) United States $4.295B 46.40
NewAmsterdam Pharma (NAMS) Netherlands $3.889B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $3.158B 0.00
Catalyst Pharmaceuticals (CPRX) United States $3.004B 9.58
Hypermarcas (HYPMY) Brazil $2.755B 18.91
Dyne Therapeutics (DYN) United States $2.399B 0.00
Soleno Therapeutics (SLNO) United States $2.231B 0.00
Guardian Pharmacy Services (GRDN) United States $2.145B 41.32
Avadel Pharmaceuticals (AVDL) Ireland $2.118B 0.00
Ocular Therapeutix (OCUL) United States $1.952B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.904B 22.56
Ardelyx (ARDX) United States $1.779B 0.00
Harrow (HROW) United States $1.753B 107.55
Enliven Therapeutics (ELVN) United States $1.746B 0.00
Definium Therapeutics (DFTX) United States $1.665B 0.00
Oruka Therapeutics (ORKA) United States $1.600B 0.00
Relay Therapeutics (RLAY) United States $1.546B 0.00
Amylyx Pharmaceuticals (AMLX) United States $1.535B 0.00
Collegium Pharmaceutical (COLL) United States $1.505B 7.45
BioCryst Pharmaceuticals (BCRX) United States $1.345B 79.75
Evotec AG (EVO) Germany $1.254B 0.00
Xeris Biopharma Holdings (XERS) United States $1.163B 0.00
Savara (SVRA) United States $1.078B 0.00
Theravance Biopharma (TBPH) United States $1.038B 43.57
Cronos Group (CRON) Canada $1.007B 0.00
ARS Pharmaceuticals (SPRY) United States $0.991B 0.00
Aktis Oncology (AKTS) United States $0.961B 0.00
Xencor (XNCR) United States $0.829B 0.00
Esperion Therapeutics (ESPR) United States $0.813B 0.00
KalVista Pharmaceuticals (KALV) United States $0.753B 0.00
Nektar Therapeutics (NKTR) United States $0.749B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.742B 17.54
Bioventus (BVS) United States $0.704B 14.42
Rigel Pharmaceuticals (RIGL) United States $0.620B 5.53
ProKidney (PROK) United States $0.563B 0.00
Altimmune (ALT) United States $0.550B 0.00
Lexeo Therapeutics (LXEO) United States $0.523B 0.00
4D Molecular Therapeutics (FDMT) United States $0.514B 0.00
Aquestive Therapeutics (AQST) United States $0.501B 0.00
Zevra Therapeutics (ZVRA) United States $0.484B 0.00
Lyell Immunopharma (LYEL) United States $0.482B 0.00
Elite Pharmaceuticals (ELTP) United States $0.481B 0.00
Siga Technologies (SIGA) United States $0.480B 6.57
Organogenesis (ORGO) United States $0.478B 0.00
Nature's Sunshine Products (NATR) United States $0.461B 27.43
USANA Health Sciences (USNA) United States $0.390B 10.89
Aclaris Therapeutics (ACRS) United States $0.387B 0.00
Akebia Therapeutics (AKBA) United States $0.369B 0.00
Protara Therapeutics (TARA) United States $0.343B 0.00
Aldeyra Therapeutics (ALDX) United States $0.333B 0.00
Cybin (HELP) Canada $0.298B 0.00
Relmada Therapeutics (RLMD) United States $0.285B 0.00
Larimar Therapeutics (LRMR) United States $0.279B 0.00
Journey Medical (DERM) United States $0.278B 0.00
Enlivex Therapeutics (ENLV) Israel $0.275B 0.00
Avalo Therapeutics (AVTX) United States $0.263B 0.00
OmniAb (OABI) United States $0.245B 0.00
Profound Medical (PROF) Canada $0.236B 0.00
Heron Therapeutics (HRTX) United States $0.231B 0.00
MediWound (MDWD) Israel $0.228B 0.00
Achieve Life Sciences (ACHV) Canada $0.226B 0.00
Silence Therapeutics (SLN) United Kingdom $0.224B 0.00
Context Therapeutics (CNTX) United States $0.209B 0.00
Minerva Neurosciences (NERV) United States $0.208B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.199B 0.00
Surrozen (SRZN) United States $0.195B 0.00
Innate Pharma SA (IPHYF) France $0.181B 0.00
Galectin Therapeutics (GALT) United States $0.181B 0.00
AleAnna (ANNA) United States $0.179B 0.00
Century Therapeutics (IPSC) United States $0.149B 0.00
VAXART, INC (VXRT) United States $0.146B 0.00
Unicycive Therapeutics (UNCY) United States $0.144B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.137B 0.00
Prelude Therapeutics (PRLD) United States $0.136B 0.00
Inhibikase Therapeutics (IKT) United States $0.128B 0.00
Avita Medical (RCEL) United States $0.119B 0.00
Korro Bio (KRRO) United States $0.118B 0.00
Karyopharm Therapeutics (KPTI) United States $0.115B 0.00
Cardiol Therapeutics (CRDL) Canada $0.111B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.110B 0.00
Incannex Healthcare (IXHL) Australia $0.100B 0.00
Vivani Medical (VANI) United States $0.098B 0.00
Cassava Sciences (SAVA) United States $0.098B 0.00
Pyxis Oncology (PYXS) United States $0.094B 0.00
Champions Oncology (CSBR) United States $0.091B 38.53
Assertio Holdings (ASRT) United States $0.082B 0.00
PolyPid (PYPD) Israel $0.072B 0.00
HST Global (HSTC) United States $0.069B 0.00
Gain Therapeutics (GANX) United States $0.067B 0.00
Rafael Holdings (RFL) United States $0.063B 0.00
Dominari Holdings (DOMH) United States $0.061B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.058B 48.88
Procaps Group, S.A (PROCF) Luxembourg $0.058B 0.00
Fractyl Health (GUTS) United States $0.057B 0.00
NRx Pharmaceuticals (NRXP) United States $0.057B 0.00
BioNxt Solutions (BNXTF) Canada $0.056B 0.00
PMV Pharmaceuticals (PMVP) United States $0.055B 0.00
Nutriband (NTRB) United States $0.053B 0.00
Acrivon Therapeutics (ACRV) United States $0.053B 0.00
Liminatus Pharma (LIMN) United States $0.050B 0.00
Lipocine (LPCN) United States $0.047B 0.00
ElectroCore (ECOR) United States $0.044B 0.00
Telomir Pharmaceuticals (TELO) United States $0.040B 0.00
FibroGen (FGEN) United States $0.039B 0.00
Lite Strategy (LITS) United States $0.039B 0.00
Talphera (TLPH) United States $0.038B 0.00
Plus Therapeutics (PSTV) United States $0.036B 0.00
Mural Oncology (MURA) Ireland $0.035B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.033B 0.00
SCYNEXIS (SCYX) United States $0.032B 0.00
Wellgistics Health (WGRX) United States $0.028B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.028B 0.00
TherapeuticsMD (TXMD) United States $0.027B 0.00
Jupiter Neurosciences (JUNS) United States $0.021B 0.00
Natural Alternatives (NAII) United States $0.020B 0.00
Scienture Holdings (SCNX) United States $0.019B 0.00
VYNE Therapeutics (VYNE) United States $0.019B 0.00
Klotho Neurosciences (KLTO) United States $0.018B 0.00
Cosmos Health (COSM) United States $0.017B 0.00
Iterum Therapeutics (ITRM) Ireland $0.016B 0.00
Citius Pharmaceuticals (CTXR) United States $0.016B 0.00
Traws Pharma (TRAW) United States $0.016B 0.02
Vyome Holdings (HIND) United States $0.015B 0.00
Vivos Therapeutics (VVOS) United States $0.015B 0.00
Inotiv (NOTV) United States $0.014B 0.00
Mannatech (MTEX) United States $0.014B 0.00
BioLineRx (BLRX) Israel $0.013B 0.00
Tempest Therapeutics (TPST) United States $0.012B 0.00
CASI Pharmaceuticals (CASI) China $0.011B 0.00
Phio Pharmaceuticals (PHIO) United States $0.010B 0.00
Addex Therapeutics (ADXN) Switzerland $0.010B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.009B 0.00
Ainos (AIMD) United States $0.009B 0.00
BioVie (BIVI) United States $0.009B 0.00
TransCode Therapeutics (RNAZ) United States $0.008B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.008B 0.00
Curanex Pharmaceuticals Inc (CURX) United States $0.008B 0.00
Nuvilex (PMCB) United States $0.008B 0.00
Biomerica (BMRA) United States $0.007B 0.00
Mangoceuticals (MGRX) United States $0.006B 0.00
Alaunos Therapeutics (TCRT) United States $0.006B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.006B 0.00
Redhill Biopharma (RDHL) Israel $0.005B 0.00
Heatwurx (PCSA) United States $0.005B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.005B 0.00
Aptorum Group (APM) United Kingdom $0.005B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.005B 0.00
Xenetic Biosciences (XBIO) United States $0.005B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.004B 0.00
Indaptus Therapeutics (INDP) United States $0.004B 0.00
Lyra Therapeutics (LYRA) United States $0.003B 0.00
Ernexa Therapeutics (ERNA) United States $0.003B 0.00
China SXT Pharmaceuticals (SXTC) China $0.003B 0.00
XORTX Therapeutics (XRTX) Canada $0.003B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.003B 0.00
Jaguar Animal Health (JAGX) United States $0.003B 0.00
SciSparc (SPRC) Israel $0.002B 0.00
Universe Pharmaceuticals INC (UPC) China $0.002B 0.00
Clearmind Medicine (CMND) Canada $0.002B 0.00
CDT Equity (CDT) United States $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.001B 0.00
Aditxt (ADTX) United States $0.000B 0.00
Emisphere Technologies (EMIS) United States $0.000B 0.00
Grifols, S.A (GRFS) Spain $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
PainReform (PRFX) Israel $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00